As part of its ongoing investigation of legal claims involving certain antidepressant medications that may cause birth defects and other adverse consequences to infants whose mothers ingested the drugs during pregnancy, The Senators (Ret.) Firm™, LLP, commented today on a new study in the British Medical Journal which adds to growing scientific evidence that some of the drugs may significantly increase the risk of serious lung disorders in newborns.

(PRWeb January 16, 2012)

Read the full story at

( InterCure ) From today, RESPeRATE, the $300 respiratory modulator clinically-proven to lower blood pressure becomes the first non-drug hypertension treatment to be reimbursed by UK's National Health Service Drug Tariff under a newly created sub-section 'Devices for the adjunctive treatment of hypertension. The NHS pioneering decision to set up a new medical device category to supplement the ...

LONDON, February 1, 2012 /PRNewswire/ --From today, RESPeRATE: the interactive respiratory modulator clinically-proven to lower blood pressure - will be available to all hypertensive patients on NHS prescription. ...

LONDON, February 1, 2012 /PRNewswire/ --From today, an innovative non-drug, non-invasive treatment for high blood pressure will be made available to all hypertensive patients on NHS prescription. RESPeRATE ...

LONDON, February 1, 2012 /PRNewswire/ --From today, RESPeRATE: the interactive respiratory modulator clinically-proven to lower blood pressure - will be available to all hypertensive patients on NHS prescription. ...